- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Zydus Faces Rs 1.18 Crore GST Blow as Appellate Authority Upholds Tax Demand, Penalty

New Delhi: Zydus Lifesciences has said that the Appellate Authority of the Central Goods and Services Tax Appeals Commissionerate, Chandigarh, has upheld a GST demand and penalty order against the company related to alleged wrongful input tax credit claims.
The appeal order pertains to a demand of Rs 1.71 million and a penalty of Rs 10.12 million for the period between July 2017 and March 2021. The matter relates to various issues identified during a GST audit, according to the company’s regulatory filing.
Zydus Lifesciences stated that it had earlier challenged the original order before the appellate authority after receiving the demand order in January 2025. However, the appellate authority has now upheld both the demand and the penalty amount.
According to the company, the allegations relate to excess or wrongful input tax credit availed during the audit period. The order was received from the appellate authority on May 11, 2026.
As per the Zydus Lifesciences regulatory disclosure, the company plans to file a second appeal before the Goods and Services Tax Appellate Tribunal (GSTAT) against the latest order.
The company further clarified that the matter is not expected to have any material financial impact on its operations or overall business activities.
M. Pharm (Pharmaceutics)
Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

